ByTrending Posts
How Will Eli Lilly’s New $220,000 sq ft Hyderabad Tech Hub and…
Key Highlights Strategic Digital Operations Hub Anchors Eli Lilly’s Global Innovation AmbitionsEli Lilly’s Hyderabad facility located in Gachibowli…
Is AbbVie’s $15.4 Billion Q2 Surge and Strategic…
Key Highlights Strong Q2 Financial Performance and Guidance RaiseAbbVie reported Q2 2025 net revenues of $15.423 billion, up…
How Will METiS Technologies’ RMB 400 Million Series…
Key Highlights Strong Capital Infusion to Accelerate AI-Driven Nanotechnology DevelopmentThe recent RMB 400 million (~$57 million) financing round…
How Will Lantern Pharma’s PredictBBB.ai Advance with 94%…
Key Highlights Breakthrough AI Methodology Sets New Industry BenchmarkLantern’s proprietary ensemble of machine learning algorithms—including logistic regression, random…
Can Phare Bio’s AI-Driven Antibiotic Discovery Win Herald…
Key Highlights Harnessing Generative AI to Revolutionize Antibiotic DiscoveryPhare Bio leverages cutting-edge AI to drastically shorten the traditionally…
Will AbbVie’s $1 Billion Move to Acquire Gilgamesh…
Key Highlights Advanced Acquisition Talks Reflect Growth Strategy Amid Sector InterestAbbVie, following over $20 billion in acquisitions since…
How Will Ambience Healthcare’s $243M Series C Propel…
Key Highlights Transforming Clinical Documentation and Workflow with Ambient AIAmbience’s platform listens passively to clinical encounters, generating structured,…
What Impact Will the Trump Administration’s Private Health…
Key Highlights Transforming Access to Health Data Through Private Sector-Led InnovationThe Trump Administration aims to modernize healthcare with…
Can Viridian Therapeutics’ $70M Collaboration with Kissei Pharmaceutical…
Key Highlights Strategic Collaboration Combines Strengths to Advance TED Treatment in JapanViridian Therapeutics partners exclusively with Kissei Pharmaceutical…
Trending Posts
Latest Stories
Can Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience Into 2026?
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked…
Can Novartis’ 2025 Approvals and Launches Strengthen Its Position Across Oncology, Neuroscience, and Rare Diseases Into 2026?
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple…
Can Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology, Immunology, and MedTech Into 2026 and Beyond?
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver Disease Into 2026 and Beyond?
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025…
Gallery
